Discovery of new anti-depressants from structurally novel 5-HT3 receptor antagonists: Design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides
- 1 February 2011
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (4), 1253-1256
- https://doi.org/10.1016/j.bmcl.2010.12.064
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Effect of acute and chronic treatment with QCF-3 (4-benzylpiperazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT3 receptor antagonist, in animal models of depressionPharmacological Reports, 2010
- The neuronal 5-HT3 receptor network after 20 years of research — Evolving concepts in management of pain and inflammationEuropean Journal of Pharmacology, 2007
- Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation studyInternational Clinical Psychopharmacology, 2004
- Anxiolytic-like effects of DAIZAC, a selective high-affinity 5-HT3 receptor antagonist, in the mouse elevated plus-mazePharmacology Biochemistry and Behavior, 2001
- Third‐generation antidepressantsMedicinal Research Reviews, 1993
- Anxiolytic Potential of 5‐HT3 Receptor AntagonistsBasic & Clinical Pharmacology & Toxicology, 1992
- 5-HT3 receptor antagonists reverse helpless behaviour in ratsEuropean Journal of Pharmacology, 1992
- Primary Structure And Functional Expression of the 5HT 3 Receptor, A Serotonin-gated Ion ChannelScience, 1991
- The Toxicity of Antidepressants in Overdose: Incidence and MechanismsInternational Review of Psychiatry, 1990
- Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in ratsEuropean Journal of Pharmacology, 1989